Tezepelumab granted Priority Review by U.S. FDA
The Pharma Data
JULY 8, 2021
Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.(2,6,9) Reese, M.D.,
Let's personalize your content